Kanwal Raghav

33PUBLICATIONS
211CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|Apr 21, 2026
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

|Nov 24, 2025
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.

Taiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav

|Oct 19, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.

Timothy A Yap, David J Kwiatkowski, Ibiayi Dagogo-Jack

|Jul 31, 2025
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial.

Scott Kopetz, Valentina Boni, Ken Kato

|Jul 16, 2025
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Andrew J Pellatt, Alisha Bent, Nicholas Hornstein

Pageof 6

Frequent Collaborators

12 joint publications

Scott Kopetz

9 joint publications

Michael Overman

7 joint publications

John Paul Shen

7 joint publications

N Arvind Dasari